trending Market Intelligence /marketintelligence/en/news-insights/trending/id3wblkn_vr3a7sbmns9uq2 content esgSubNav
In This List

Reata Pharmaceuticals closes offering of class A common stock

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Reata Pharmaceuticals closes offering of class A common stock

Reata Pharmaceuticals Inc. closed an underwritten public offering of 3,450,000 class A common shares, priced $72 each.

Shares sold include 450,000 shares acquired by the underwriters as part of the full exercise of the overallotment option.

The Irving, Texas-based drug developer raised gross proceeds of about $248.4 million. Net proceeds will go toward working capital and general corporate purposes, including development of bardoxolone methyl and omaveloxolone, filing of new drug applications and commercialization of potential products.

Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Co. Inc. and Cantor Fitzgerald & Co. acted as joint book-running managers for the offering, with Ladenburg Thalmann & Co. Inc. as co-manager.